On October 29, 2020 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), reported that it has treated the first patient in the sixth and final cohort of its National Cancer Institute (NCI)-supported, multi-center ReSPECT Phase 1 dose-finding clinical trial evaluating Rhenium NanoLiposomes (RNL) for the treatment of recurrent glioblastoma (GBM) (Press release, PLUS THERAPEUTICS, OCT 29, 2020, View Source [SID1234572297]). Initiation of the sixth dose cohort follows successful completion of the fifth cohort and clearance from the ReSPECT trial’s Data and Safety Monitoring Board (DSMB).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The sixth cohort of the ReSPECT trial includes an increase in both the RNL drug volume and radiation dose to 8.8 milliliters and 22.3 millicuries, respectively. RNL is designed to safely, effectively and conveniently deliver a very high dose of radiation, with a dose that is up to 25 times greater than currently used external beam radiation therapy, directly into the brain tumor for maximum effect.

"Cohort progression in our ReSPECT trial represents another milestone toward the trial’s first major readout," said Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics. "The RNL drug volume and dose in cohort six should allow us to target the majority of glioblastoma tumors found in the recurrent setting."

Plus Therapeutics will be presenting data from the ReSPECT clinical trial at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting being held virtually November 19-21, 2020. The Company will be providing detailed interim safety, tolerability, dosing and efficacy data of RNL in adults with recurrent GBM after standard surgical, radiation and chemotherapy treatment.

ReSPECT is currently supported by an award from the NCI. The Company plans to complete enrollment in the Phase 1 trial by the end of 2020 and in parallel will utilize its recently awarded U.S. Food and Drug Administration Orphan Drug and Fast Track designations to determine the next steps for the program.

On October 29, 2020 Ziopharm Oncology, Inc. (Nasdaq: ZIOP), reported the Company will host a conference call and webcast on Thursday, November 5, at 4:30 pm EDT to provide a corporate update and discuss financial results for the third quarter ended September 30, 2020 (Press release, Ziopharm, OCT 29, 2020, View Source [SID1234569927]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call can be accessed by dialing 1-800-920-9723 (U.S. and Canada) or 1-212-231-2932 (international). The passcode for the conference call is 21971110. To access the live webcast or the subsequent archived recording, visit the "Investors" section of the Ziopharm website at www.ziopharm.com. The webcast will be recorded and available for replay on the Company’s website for two weeks.

On October 29, 2020 Geron Corporation (Nasdaq: GERN) reported that it will release its third quarter 2020 financial results after the market closes on Thursday, November 5, 2020 via press release, which will be available on the Company’s website at www.geron.com/investors (Press release, Geron, OCT 29, 2020, View Source [SID1234569806]). Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live, listen-only webcast will be available on the Company’s website at www.geron.com/investors/events. If you are unable to listen to the live call, an archived webcast will be available on the Company’s website for 30 days.

Participants may access the conference call live via telephone by pre-registering online using the following link, View Source Upon registration, a phone number, Direct Event Passcode and unique Registrant ID will be sent via email. This information will be needed in order to enter the conference call. Participants are advised to pre-register at least 10 minutes prior to joining the call.

On October 29, 2020 Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, reported that it has entered into a Licence and Collaboration Agreement with Laboratory Corporation of America Holdings, known as LabCorp (NYSE: LH) that will support the development of immuno-oncology products or services (Press release, Immutep, OCT 29, 2020, View Source [SID1234569750]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Over the years, Immutep has generated a significant amount of know-how in immuno-oncology, specifically in terms of LAG-3", said Marc Voigt, CEO of Immutep.

Under the terms of the Agreement, Immutep is eligible to receive an upfront fee of US$125,000 and potential further commercial milestones and service payments. The milestone payments, which consist of up to three payments, are tied to the commercialisation of new drugs or new indications of existing drugs that requires use of an immuno-oncology diagnostic being developed by LabCorp.

The Agreement will continue until such time as the licensed technology and associated intellectual property have been exhausted and are in the public domain, or until terminated by either party.

The collaboration with LabCorp is unrelated to any of Immutep’s own in-house pharmaceutical development programs in cancer or autoimmune disease. Significantly, it enables Immutep to enter the immuno-oncology diagnostics field.

On October 29, 2020 Bellicum Pharmaceuticals, Inc. (Nasdaq:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, reported the pricing of an underwritten offering priced at-the-market under Nasdaq rules of 4,149,378 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying warrants to purchase up to 4,149,378 shares of common stock (Press release, Bellicum Pharmaceuticals, OCT 29, 2020, View Source [SID1234569654]). Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one warrant to purchase one share of common stock at a combined effective price of $6.025. The offering is expected to involve a limited number of healthcare-dedicated institutional investors, including significant participation from two of Bellicum’s existing healthcare-dedicated institutional investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. is acting as sole book-running manager for the offering.

The gross proceeds to Bellicum from the offering are expected to be approximately $25.0 million, before deducting underwriting discounts and commissions and other offering expenses payable by Bellicum, excluding any proceeds that may be received upon exercise of the common warrants. Bellicum anticipates using the net proceeds from the offering, together with its existing capital resources, to fund ongoing and planned BPX-601 and BPX-603 clinical trials, and for general corporate purposes, including research and development and to fund working capital.

The common warrants will be immediately exercisable at an exercise price of $6.50 per share of common stock and will expire five years from the date of issuance. The shares of common stock or the pre-funded warrants, and the accompanying common warrants, can only be purchased together in the offering but will be issued separately and will be immediately separable upon issuance. The offering is expected to close on or about November 3, 2020, subject to satisfaction of customary closing conditions.

The securities described above are being sold by Bellicum pursuant to a shelf registration statement filed by Bellicum with the Securities and Exchange Commission (SEC), which was declared effective on July 30, 2019. The securities will be sold only by means of a prospectus, including a prospectus supplement, forming a part of the effective registration statement. Electronic copies of the prospectus supplement and accompanying base prospectus may be obtained, when available, by contacting H.C. Wainwright & Co., LLC, by emailing [email protected] or by calling 646-975-6996, or by visiting the SEC’s website at View Source

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation,

or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.